1. Home
  2. VTYX vs EHTH Comparison

VTYX vs EHTH Comparison

Compare VTYX & EHTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • EHTH
  • Stock Information
  • Founded
  • VTYX 2018
  • EHTH 1997
  • Country
  • VTYX United States
  • EHTH United States
  • Employees
  • VTYX N/A
  • EHTH N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • EHTH Specialty Insurers
  • Sector
  • VTYX Health Care
  • EHTH Finance
  • Exchange
  • VTYX Nasdaq
  • EHTH Nasdaq
  • Market Cap
  • VTYX 154.9M
  • EHTH 176.1M
  • IPO Year
  • VTYX 2021
  • EHTH 2006
  • Fundamental
  • Price
  • VTYX $1.27
  • EHTH $5.62
  • Analyst Decision
  • VTYX Buy
  • EHTH Buy
  • Analyst Count
  • VTYX 4
  • EHTH 4
  • Target Price
  • VTYX $11.33
  • EHTH $6.38
  • AVG Volume (30 Days)
  • VTYX 1.3M
  • EHTH 166.8K
  • Earning Date
  • VTYX 05-08-2025
  • EHTH 05-07-2025
  • Dividend Yield
  • VTYX N/A
  • EHTH N/A
  • EPS Growth
  • VTYX N/A
  • EHTH N/A
  • EPS
  • VTYX N/A
  • EHTH N/A
  • Revenue
  • VTYX N/A
  • EHTH $532,409,999.00
  • Revenue This Year
  • VTYX N/A
  • EHTH $1.38
  • Revenue Next Year
  • VTYX N/A
  • EHTH $8.81
  • P/E Ratio
  • VTYX N/A
  • EHTH N/A
  • Revenue Growth
  • VTYX N/A
  • EHTH 17.56
  • 52 Week Low
  • VTYX $0.78
  • EHTH $3.58
  • 52 Week High
  • VTYX $5.66
  • EHTH $11.36
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 56.45
  • EHTH 37.31
  • Support Level
  • VTYX $1.14
  • EHTH $5.88
  • Resistance Level
  • VTYX $1.32
  • EHTH $6.24
  • Average True Range (ATR)
  • VTYX 0.09
  • EHTH 0.31
  • MACD
  • VTYX 0.04
  • EHTH 0.08
  • Stochastic Oscillator
  • VTYX 90.22
  • EHTH 24.69

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About EHTH eHealth Inc.

eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.

Share on Social Networks: